Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1980;97(1):71-9.
doi: 10.1007/BF00411280.

Comparison of survival in nonresected well differentiated and poorly differentiated adenocarcinoma of the lung

N Saijo, H Niitani, K Tominaga, K Eguchi, H Koketsu, T Fujino, S Ishikawa

Comparison of survival in nonresected well differentiated and poorly differentiated adenocarcinoma of the lung

N Saijo et al. J Cancer Res Clin Oncol. 1980.

Abstract

One hundred nineteen cases of advanced adenocarcinoma of the lung were divided into well differentiated adenocarcinoma (72 cases) and poorly differentiated adenocarcinoma (47 cases) histologically and/or cytologically. The median survival of 72 cases of well differentiated adenocarcinoma (7.9 months) was significantly (P less than 0.025) longer than that of poorly differentiated adenocarcinoma (4.9 months) irrespective of stage, difference in treatment regimen, or response to treatment. In 9 evaluable cases, the objective response rate to chemotherapy was 25% (6/24) in poorly differentiated adenocarcinoma and 11.3% (8/71) in well differentiated adenocarcinoma, respectively. In 45 patients who received a combination of chemotherapy and radiotherapy, the median survival of 22 well differentiated adenocarcinomas (11.8 months) was significantly (P less than 0.05) longer than than of 23 poorly differentiated adenocarcinomas (5.6 months). The same tendency was observed in 74 patients who received chemotherapy alone. Analysis based on the grade of differentiation is essential for the accurate assessment of the efficacy of treatment in adenocarcinomas of the lung.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bergsagel DE, Jenkins RDT, Pringel JF (1972) Lung cancer: Clinical trial of radiotherapy alone vs. radiotherapy plus cyclophosphamide. Cancer 30:621–627 - PubMed
    1. Bitran JD, Dresser RK, DeMesser T, Shapiro CM, Billings A, Rubenstein L, Evans R, Colman M, Griem M, Golomb HM (1978) Combined modality therapy for stage III non-oat cell bronchogenic carcinoma. Cancer Treat Rep 62:327–332 - PubMed
    1. Brittell JC, Eagan RT, Ingle JN, Creagan ET, Rubin J, Frytak S (1978) cis-dichlorodiammineplatinum (II) alone follwed by adrinamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum (II), adriamycin, and cyclophophamide in combination for adenocarcinoma of the lung. Cancer Treat Rep 62:1207–1210 - PubMed
    1. Issel BF, Valdivieso M, Body GP (1978) Chemotherapy for adenocarcinoma and large cell anaplastic carcinoma of the lung with futraful, adriamycin, and cis-dichlorodiammine-platinum. Cancer Treat Rep 62:1089–1091 - PubMed
    1. Koketsu H, Subtype of adenocarcinoma classified by cytology. (Personal communication)

Substances

LinkOut - more resources